MedTrace Logo

Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure

NCT03480633 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-12-09

No results posted yet for this study

Summary

In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.

Conditions

  • Heart Failure With Normal Ejection Fraction
  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure, Right Sided
  • Heart Failure With Mid Range Ejection Fraction
  • Cardiovascular Risk Factor

Sponsors & Collaborators

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Hanna Gaggin, MD, MPH · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-07
Primary Completion
2026-04-06
Completion
2027-10-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03480633 on ClinicalTrials.gov